Page 1

EX - 99.1 2 osur - ex99_1.htm EX - 99.1 OraSure Technologies , Inc. EXHIBIT 99.1 Investor Contact : Scott Gleason Interim CFO SVP Investor Relations & Corp. Communications 484-425-0588 sgleason@orasure.com Media Contact : Amy Koch Sr. Mgr . Corporate Communications 484-523-1815 media@orasure.com OraSure Technologies Reports 3Q21 Revenue of $ 53.9 Million , Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab ™ Growth in FY22 Third quarter revenue of $ 53.9 million grew 12 % year - over - year ; excluding COVID - 19 product revenues , revenues for the quarter grew 37 % from the prior year , demonstrating strong growth TM OraSure signs three major U.S. government contracts providing $ 205 million in government InteliSwab procurement , $ 109 million for InteliSwab ™ manufacturing capacity build out , and $ 13.6 million to pursue full FDA 510 ( k ) clearance and CLIA waiver for InteliSwab ™ ☐ Company increases financial guidance range for fiscal year 2021 and is now expecting revenues of $ 230- $ 233 million Management to Host Analyst / Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM , PA , November 3 , 2021 ( GLOBE NEWSWIRE ) -- OraSure Technologies , Inc. ( NASDAQ : OSUR ) , a leader in point - of - care and home diagnostic tests , specimen collection devices , and microbiome laboratory and analytical services , today announced its financial results for the three months ended September 30 , 2021 . " OraSure demonstrated strong revenue growth and laid the foundation to dramatically scale the size of the Company in fiscal year 2022. Importantly , we signed three major contracts this quarter with the U.S. government : $ 205 million for InteliSwab ™ COVID - 19 Rapid Test procurement , $ 109 million for InteliSwab ™ manufacturing capacity build out , and $ 13.6 million to pursue full FDA 510 ( k ) clearance for InteliSwab ™ . These contracts position OraSure as an important part of the government's global pandemic response and will lower our cost per product and broaden our customer reach . ” Dr. Tang continued , " We continue to view InteliSwab ™ as an integral part of our long - term growth strategy , as an entrance into the respiratory rapid test market -- the largest point - of - care testing market in the world . This provides an unprecedented opportunity to strategically transform our company and improve our long - term growth profile . Given the strong growth we anticipate in 2022 , we are highly focused on execution and ramping our manufacturing production to meet demand . We are also actively working to bolster innovation both through internal research and development and external M & A which we believe will drive long - term sustained growth and value for our stockholders . " 1